HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wakat, M. A. Articles by Watson, N. E. Search for Related Content PubMed PubMed Citation Articles by Wakat, M. A. Articles by Watson, N. E., Jr.

Comparison of Tc-99m Pyrophosphate and Tc-99m Hydroxymethylene Diphosphonate in Acute Myocardial Infarction: Concise Communication

Bowman Gray School of Medicine, Winston-Salem, North Carolina

Correspondence: For reprints contact: Robert J. Cowan, M.D., Section of Nuclear Medicine, Bowman Gray School of Medicine, 300 S. Hawthorne Rd. Winston-Salem, NC 27103.

ABSTRACT

A clinical comparison between a new bone seeking radiopharmaceutical, Tc-99m hydroxymethylene diphosphonate (TcHMDP) and the standard agent, Tc-99m pyrophosphate (TcPPi), was performed in 18 patients with acute myocardial infarction. Each patient was imaged initially with either TcHMDP or TcPPi, and imaged 24 hr later with the other tracer. All 18 patients had images positive for acute myocardial infarction with TcPPi, whereas 16 of 18 patients (89%) had positive studies with TcHMDP. The TcPPi images were graded significantly superior to those obtained with TcHMDP in 61% of the patients, and they were equal in 33%. In only one patient (6%) was TcHMDP better. The results indicate that compared with TcHMDP, TcPPi not only has a superior sensitivity for acute myocardial infarction but also has a significantly increased intensity of uptake in positive areas. TcPPi remains the agent of choice for myocardial infarct imaging.

FOOTNOTES

^* Current Address: Nuclear Medicine Dept., Roanoke Memorial Hospital, Roanoke, VA 24033.